RLMD

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology company founded in 2004 and headquartered in Coral Gables, Florida. The company has evolved from focusing primarily on a single drug candidate for depression treatment to building a diversified pipeline of central nervous system therapies and other medical treatments. After going public in 2014, Relmada has undergone significant strategic pivots in recent years, including acquiring new product candidates and expanding beyond its original depression treatment focus following mixed clinical trial results.